The power of bioactive glass and the consistency of demineralized allograft bone in a single product.
NanoFUSE® Bioactive Matrix is a novel bone graft substitute expressly designed to optimize surgical handling, graft stability and osteoproductivity in orthopedic and spine surgery. NanoFUSE® Bioactive Matrix incorporates human demineralized bone matrix (DBM) and synthetic calcium phosphor-silicate particulate material particles (45s5 bioactive glass), both coated with gelatin.
LEARN MORE
Offered in multiple forms the active components are combined with a natural carrier to encapsulate the bioglass and demineralized bone while not interfering with the clinical usefulness of the product. The novel and patented coating process produces a product that is easy to prepare with optimal handling characteristics.
Inspired by the mucus secreted by the Dusky Arion slug, researchers at the Wyss Institute have developed a surgical adhesive that can adhere to wet and dynamic surfaces inside the body, including the heart, lung, tendons, cartilage, and bone. Coupled with a novel tough hydrogel, this surgical adhesive could replace existing wound closure methods. Amend Surgical will develop the tough gel into an alternative to the uncomfortable, difficult-to-sew sutures that are the current standard of care in oral surgery.
Co-Founder and Chief Executive Officer, Robby Lane, has worked for over 25 years in the medical device and biologics fields. He was President and Managing Director at Tutogen Medical in Neunkirchen, Germany where he led the financial and global market expansion of this division of RTI Surgical. Most recently, he worked as Executive Vice President of Commercial Distribution at RTI Surgical where he drove product development and the exponential expansion of the company’s commercial partnerships.
Co-Founder Ronald R. Cobb, Ph.D., has worked for over 20 years in the pharmaceutical and medical device fields. While he was Director of Research at RTI Biologics, over 20 new products and line extensions were launched. Ron is currently Chief Scientific Officer at Nanotherapeutics, Inc., focusing on the R&D and Manufacturing of various vaccine and recombinant protein pharmaceutics.
